Johnson & Johnson (NYSE: JNJ) recently released its Q1 earnings, surpassing analyst estimates on both revenue and earnings. The company posted adjusted earnings of $2.77 per share on revenue of $ ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Shares of multinational healthcare company Johnson & Johnson (NYSE:JNJ) fell 5.6% in the morning session after a judge in Texas rejected the company's third attempt to use bankruptcy as a legal ...

Johnson & Johnson (JNJ) beat Wall Street expectations in its first-quarter earnings report and raised its 2025 sales forecast by $700 million, even though sales are expected to dip due to the loss ...